• +1-646-491-9876
    • +91-20-67278686

    Search

    Bromodomain Containing Protein 4 Pipeline Review H1 2017

    Bromodomain Containing Protein 4 Pipeline Review H1 2017

    • Report Code ID: RW0001851072
    • Category Life Sciences
    • No. of Pages 113
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2017

    Summary

    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 39 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 21 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Genetic Disorders, Ophthalmology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Solid Tumor, Multiple Myeloma (Kahler Disease) , Breast Cancer, Myelodysplastic Syndrome, Diffuse Large B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Hematological Tumor, Inflammation, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) , Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Atherosclerosis, Colorectal Cancer, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Alzheimer's Disease, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Burkitt Lymphoma, Carcinomas, Chronic Kidney Disease (Chronic Renal Failure) , Chronic Lymphocytic Leukemia (CLL) , Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , Coronary Artery Disease (CAD) (Ischemic Heart Disease) , Fabry Disease, Follicular Lymphoma, Glioblastoma Multiforme (GBM) , Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) , Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Lung Cancer, Malignant Pleural Mesothelioma, Melanoma, Metastatic Brain Tumor, Metastatic Liver Cancer, Nephropathy, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD) / Peripheral Vascular Disease (PVD) , Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) , Pre-Diabetes/Impaired Glucose Tolerance, Renal Cell Carcinoma, Retinal Degeneration, Rheumatoid Arthritis, Small-Cell Lung Cancer, Substance (Drug) Abuse and Systemic Lupus Erythematosus.

    Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
    - The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
    Aptose Biosciences Inc
    Arvinas Inc
    AstraZeneca Plc
    ConverGene LLC
    Dybly AG
    F. Hoffmann-La Roche Ltd
    Forma Therapeutics Inc
    GlaxoSmithKline Plc
    Incyte Corp
    Kainos Medicine Inc
    Merck & Co Inc
    Nuevolution AB
    Plexxikon Inc
    Resverlogix Corp
    Trillium Therapeutics Inc
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
    apabetalone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARCC-29 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARV-763 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARV-771 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARV-825 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-5153 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    birabresib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CG-202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CG-223 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CG-250 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CK-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CPI-0610 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DCBD-005 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DYB-186 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EP-11313 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FT-1101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-525762 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INCB-54329 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KM-601 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MA-2014 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MS-417 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MZ-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NEO-2734 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NUE-7770 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PLX-51107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-6146 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RVX-2135 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-10 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SF-2523 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SF-2535 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Bromodomain Containing Protein-4 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BRD4 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BRD4 for Ovarian Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRX-3177 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TTI-281 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZBC-260 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZEN-3694 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
    Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
    Featured News & Press Releases
    Jun 05, 2017: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
    Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
    May 31, 2017: Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
    May 30, 2017: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
    May 23, 2017: Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
    May 15, 2017: Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
    May 01, 2017: SignalRx Discloses its Novel Immuno-Oncology Program Approach at the 12th Annual Drug Discovery Chemistry 2017 Meeting
    Apr 25, 2017: SignalRx to Present at the 12th Annual Drug Discovery Chemistry 2017 Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer
    Apr 03, 2017: SignalRx to Present at the AACR Annual Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer
    Mar 17, 2017: Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
    Mar 15, 2017: Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
    Feb 23, 2017: Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
    Feb 13, 2017: Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy and Neurodegenerative Eye Disease
    Feb 01, 2017: SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication
    Jan 23, 2017: Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1)
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Aptose Biosciences Inc, H1 2017
    Pipeline by Arvinas Inc, H1 2017
    Pipeline by AstraZeneca Plc, H1 2017
    Pipeline by ConverGene LLC, H1 2017
    Pipeline by Dybly AG, H1 2017
    Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Pipeline by Forma Therapeutics Inc, H1 2017
    Pipeline by GlaxoSmithKline Plc, H1 2017
    Pipeline by Incyte Corp, H1 2017
    Pipeline by Kainos Medicine Inc, H1 2017
    Pipeline by Merck & Co Inc, H1 2017
    Pipeline by Nuevolution AB, H1 2017
    Pipeline by Plexxikon Inc, H1 2017
    Pipeline by Resverlogix Corp, H1 2017
    Pipeline by Trillium Therapeutics Inc, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Aptose Biosciences Inc
    Arvinas Inc
    AstraZeneca Plc
    ConverGene LLC
    Dybly AG
    F. Hoffmann-La Roche Ltd
    Forma Therapeutics Inc
    GlaxoSmithKline Plc
    Incyte Corp
    Kainos Medicine Inc
    Merck & Co Inc
    Nuevolution AB
    Plexxikon Inc
    Resverlogix Corp
    Trillium Therapeutics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//bromodomain-containing-protein-4-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//bromodomain-containing-protein-4-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//bromodomain-containing-protein-4-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments